Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma

Fig. 3

In-vivo and ex-vivo biodistribution of AT101. A bar chart of the in-vivo biodistribution, using VIVOVISION IVIS®Lumina, of AT101 (1 nmol of Cy5.5) in comparison with the negative control unspecific IgM (1 nmol of Cy5.5). Data are reported as average efficiency mean ± SD (n = 4). P-value was calculated using t-test. ns: ≥ 0.05; *: 0.05 < p ≤ 0.01; **: 0.01 < p ≤ 0.001. B bar chart of the ex-vivo biodistribution, using VIVOVISION IVIS®Lumina, of AT101 (1 nmol of Cy5.5) in comparison with the negative control unspecific IgM (1 nmol of Cy5.5). Data are reported as average efficiency mean ± SD (n = 4). P-value was calculated using t-test. ns: ≥ 0.05

Back to article page